We are proud to unveil new findings about our Integrated Risk Tool for cardiovascular disease, which has just achieved another significant validation. A recent study led by the University of Leicester, published in the esteemed European Heart Journal, underscores the transformative potential of our tool in early prevention.

The collaboration, across multiple therapeutic areas, will evaluate how polygenic risk scores could be used to improve clinical trial design and efficiency

The wellness offering utilizes advanced genetics to provide personalized risk information for common and preventable diseases, including heart disease, diabetes, breast and prostate cancer

We are delighted to share exciting news in cardiovascular prevention! Genomics plc's study in the European Journal of Preventive Cardiology integrates genetic risk factors for advanced heart disease prediction with QRISK®2. This HEART Study demonstrates that Integrated Risk Tools (IRTs) are a potent combination outperforming existing tools.

An article in The Financial Times by Hannah Kuchler announced the news of the Oxford university spinout's successful fundraise to help predict disease leveraging polygenic risk scores.

Genomics plc has been selected from among more than 1,500 applications to be included in Bloomberg’s inaugural 25 UK Startups to Watch list. Bloomberg canvassed the UK to find 25 startups that represent the diversity and innovation of the country's startup scene. The Editors wanted to hear about companies that are growing fast, working on something truly unique and come from a diverse group of founders from all over the UK. Genomics plc co-Founder, Professor Sir Peter Donnelly, was also one of three founders from companies in the list to be on stage at the Bloomberg Technology Summit to discuss the Genomics plc story and the wider life sciences/tech sector.

Genomics plc has made it into the Newsweek list of the UK's 100 Most Loved Workplaces 2023. The list is based on feedback from companies' employees and the rankings encompass a company's commitment to equality, diversity and inclusion, its dedication to employee growth and development and its ability to adapt to the needs of its workforce.

Genomics plc has today announced that Mark Toms and Nick DeFilippo have joined its leadership team as Chief Medical Officer and Chief Commercial Officer, respectively. Both join the company’s executive leadership team.

Genomics plc has reported significant, positive results from the world’s first pilot investigating the use of genomic polygenic risk score testing to support the prevention of cardiovascular disease (CVD) in NHS clinical practice, at the American Heart Association Scientific Sessions today.

Genomics plc have today announced a partnership with Our Future Health to generate polygenic risk scores (PRS) as part of the research programme’s aim to find new ways to prevent, detect and treat common diseases such as dementia, diabetes, heart disease, stroke, and cancer.

We are proud to unveil new findings about our Integrated Risk Tool for cardiovascular disease, which has just achieved another significant validation. A recent study led by the University of Leicester, published in the esteemed European Heart Journal, underscores the transformative potential of our tool in early prevention.

The collaboration, across multiple therapeutic areas, will evaluate how polygenic risk scores could be used to improve clinical trial design and efficiency

The wellness offering utilizes advanced genetics to provide personalized risk information for common and preventable diseases, including heart disease, diabetes, breast and prostate cancer

We are delighted to share exciting news in cardiovascular prevention! Genomics plc's study in the European Journal of Preventive Cardiology integrates genetic risk factors for advanced heart disease prediction with QRISK®2. This HEART Study demonstrates that Integrated Risk Tools (IRTs) are a potent combination outperforming existing tools.

An article in The Financial Times by Hannah Kuchler announced the news of the Oxford university spinout's successful fundraise to help predict disease leveraging polygenic risk scores.

Genomics plc has been selected from among more than 1,500 applications to be included in Bloomberg’s inaugural 25 UK Startups to Watch list. Bloomberg canvassed the UK to find 25 startups that represent the diversity and innovation of the country's startup scene. The Editors wanted to hear about companies that are growing fast, working on something truly unique and come from a diverse group of founders from all over the UK. Genomics plc co-Founder, Professor Sir Peter Donnelly, was also one of three founders from companies in the list to be on stage at the Bloomberg Technology Summit to discuss the Genomics plc story and the wider life sciences/tech sector.

Genomics plc has made it into the Newsweek list of the UK's 100 Most Loved Workplaces 2023. The list is based on feedback from companies' employees and the rankings encompass a company's commitment to equality, diversity and inclusion, its dedication to employee growth and development and its ability to adapt to the needs of its workforce.

Genomics plc has today announced that Mark Toms and Nick DeFilippo have joined its leadership team as Chief Medical Officer and Chief Commercial Officer, respectively. Both join the company’s executive leadership team.

Genomics plc has reported significant, positive results from the world’s first pilot investigating the use of genomic polygenic risk score testing to support the prevention of cardiovascular disease (CVD) in NHS clinical practice, at the American Heart Association Scientific Sessions today.

Genomics plc have today announced a partnership with Our Future Health to generate polygenic risk scores (PRS) as part of the research programme’s aim to find new ways to prevent, detect and treat common diseases such as dementia, diabetes, heart disease, stroke, and cancer.

We are proud to unveil new findings about our Integrated Risk Tool for cardiovascular disease, which has just achieved another significant validation. A recent study led by the University of Leicester, published in the esteemed European Heart Journal, underscores the transformative potential of our tool in early prevention.

The collaboration, across multiple therapeutic areas, will evaluate how polygenic risk scores could be used to improve clinical trial design and efficiency

The wellness offering utilizes advanced genetics to provide personalized risk information for common and preventable diseases, including heart disease, diabetes, breast and prostate cancer

We are delighted to share exciting news in cardiovascular prevention! Genomics plc's study in the European Journal of Preventive Cardiology integrates genetic risk factors for advanced heart disease prediction with QRISK®2. This HEART Study demonstrates that Integrated Risk Tools (IRTs) are a potent combination outperforming existing tools.

An article in The Financial Times by Hannah Kuchler announced the news of the Oxford university spinout's successful fundraise to help predict disease leveraging polygenic risk scores.

Genomics plc has been selected from among more than 1,500 applications to be included in Bloomberg’s inaugural 25 UK Startups to Watch list. Bloomberg canvassed the UK to find 25 startups that represent the diversity and innovation of the country's startup scene. The Editors wanted to hear about companies that are growing fast, working on something truly unique and come from a diverse group of founders from all over the UK. Genomics plc co-Founder, Professor Sir Peter Donnelly, was also one of three founders from companies in the list to be on stage at the Bloomberg Technology Summit to discuss the Genomics plc story and the wider life sciences/tech sector.

Genomics plc has made it into the Newsweek list of the UK's 100 Most Loved Workplaces 2023. The list is based on feedback from companies' employees and the rankings encompass a company's commitment to equality, diversity and inclusion, its dedication to employee growth and development and its ability to adapt to the needs of its workforce.

Genomics plc has today announced that Mark Toms and Nick DeFilippo have joined its leadership team as Chief Medical Officer and Chief Commercial Officer, respectively. Both join the company’s executive leadership team.

Genomics plc has reported significant, positive results from the world’s first pilot investigating the use of genomic polygenic risk score testing to support the prevention of cardiovascular disease (CVD) in NHS clinical practice, at the American Heart Association Scientific Sessions today.

Genomics plc have today announced a partnership with Our Future Health to generate polygenic risk scores (PRS) as part of the research programme’s aim to find new ways to prevent, detect and treat common diseases such as dementia, diabetes, heart disease, stroke, and cancer.